The compound inhibited the Toll-like receptor 4 (TLR4) signaling pathway in the liver, reducing pro-inflammatory cytokine secretion and alleviating MASLD symptoms [146]. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.